A retail intelligence report has highlighted a decline in the availability of plus-size clothing on the British high street, amid growing popularity of weight-loss medications such as Wegovy and Mounjaro. Research by the platform Edited found that the proportion of new dresses offered in plus sizes—defined as above size 18—at major retailers like Marks & Spencer and John Lewis has dropped significantly this year.

At Marks & Spencer, the share of newly introduced plus-size dresses decreased from 34 percent in early 2024 to 27 percent over the summer. John Lewis experienced a similar trend, with new plus-size dress offerings falling from 22.3 percent to 19.2 percent during the same period. This shift raises concerns among advocates for body diversity and inclusivity in fashion, who argue that reduced availability may reinforce narrow societal standards of femininity and body size.

One shopper, who describes herself as a size 18-20 woman, recounted her experience struggling to find appropriate sizing in popular retailers. She noted limited in-store plus-size options at Zara, where XXL items were reportedly available only online, leaving physical shelves stocked predominantly with smaller sizes. Although she praised other British retailers like John Lewis and Marks & Spencer for historically carrying a broader range, she said recent visits proved disappointing as plus-size selections appeared to be diminishing.

The user pointed to the broader cultural context surrounding body positivity, which had previously contributed to improved representation and greater accessibility of fashionable clothing for larger bodies. However, she expressed frustration that the rise of GLP-1 receptor agonist drugs—like those produced by pharmaceutical company Eli Lilly—might contribute to shrinking market demand for plus sizes, potentially narrowing fashion choices for women who do not conform to smaller size ranges.

Some supporters of the weight-loss drugs emphasize the potential health benefits for individuals struggling with obesity or related medical conditions. Yet critics caution that the impact on retail trends and societal expectations risks creating a new form of body standardization, reducing inclusivity for diverse body shapes.

These developments come against a backdrop of ongoing debates about body autonomy, fashion industry practices, and the implications of pharmaceutical interventions on public perceptions of weight and health. As consumer preferences evolve, retailers face increasing pressure to balance demand with representation, while advocates continue to call for broader inclusivity in sizing and marketing strategies.